Biotech / Medical
An SI Board Since October 2009
Posts SubjectMarks Bans Symbol
14 12 0 ZIOP
Emcee:  Biocaptain Type:  Moderated
Ziopharm is an oncology-focused company with 3 portfolio products:

1) Darinaparsin, an organic arsenic derivative with in vitro activity against lung, colon, brain, melanoma, ovarian and kidney cancers; hematological cancers (leukemia, lymphoma, myelodysplastic syndromes and multiple myeloma); does not have the cardiac, neurologic or hepatic toxicity of organic arsenic

ASCO 2009: encouraging data in refractory T-cell lymphoma; NHL
Composition of matter patent: expires 2022 (many additional patents)

2) Palifosfamide--Ifosfamide metabolite without the renal and bladder toxicity of Ifosfamide and without the "fuzzy brain" of cyclophasphamide; activity against a wide range of solid tumors

Oct 2009--Phase 2 sarcoma trial stopped early due to better than anticipated efficacy
Composition of matter patent: expires in 2018

3) Indibulin--tubulin antagonist with activity against a wide range of solid tumors

phase 1/2 trial in triple-negative breast cancer due to start Q1 of 2010
Composition of matter patent: expires in 2016; 3 methods of use patents, longest of which is out to 2026
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted Pivotal, randomized control trial in rGBM to initiate by end oThe Ox-11/7/2017
13Apparently, ZIOP has finally recognized the error of their ways and decided to rPLegee-3/28/2017
12Totally frustrated. So hard to get any information on this stock. No conferencPLegee-3/21/2017
11Two big days in a row, I have no idea why, no news, but I like it!! Still thinkPLegee-2/3/2017
10I guess I was wrong about warrants, there does not seem to be any. There was a The Ox-2/2/2017
9Did not know there were warrants outstanding, thanks for that info. On another PLegee-2/2/2017
8The run from $2 to $14 was pretty amazing but was way overdone, IMO. Had the stThe Ox-2/2/2017
7Already 2M shares traded with still 2 hours of market before the close. Stock cPLegee-2/2/2017
6 [graphic] [graphic]The Ox-2/1/2017
5Of the two non-clinical obstacles in Ziop's price performance path (sector/pPLegee-2/1/2017
4From the recent (Jan '17) JPM Healthcare Conference in San Francisco, ZIOP hPLegee11/26/2017
37:13AM ZIOPHARM reports Phase 3 trial of ZIOPHARM'S palifosfamide in first-lThe Ox-2/12/2013
2Palifosfamide data expected on Friday and based on the excitement exuded by the jeffpaley-11/4/2009
1Hi all Started this post tonight to highlight what I think is an unusual companBiocaptain-10/27/2009
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.